[EXPERT SERVICES] How our macrophage-based assays are relevant to be fully exploited for testing novel therapies
Discover our macrophage-based assays, their subtleties and relevance in assessing macrophage functions and mediated immune response, and evaluating the efficacy of immunotherapeutics - either on the stimulatory M1 macrophages capacities or, especially, in relieving the suppressive functions of M2 macrophages.
[SCIENTIFIC BREAKTHROUGH] New key biomarkers predictive of the efficacy of immunotherapy in oncology
Our latest translational studies unraveled a determinant mechanism associated with resistance to immune checkpoint blockade (ICB)-based therapies. Indeed, we evidenced a correlation between the indoleamine 2,3-dioxygenase (IDO) expression, which catabolizes tryptophan toward Kynurenines, and a favorable clinical outcome of Non-Small Cell Lung Cancer patients treated with ICB.
[SCIENTIFIC EVENT] First symposium of the CONDOR consortium in Bordeaux
As part of the CONDOR consortium, we were proud to participate in its first symposiumto share with experts and KOLs the latest findings and insights on microenvironment and immunotherapy of sarcoma.